Capital Fund Management (CFM)’s Ligand Pharmaceuticals LGND Stock Holding History

Capital Fund Management (CFM)’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,091	Closed	-$434K	–	1783
2019 Q2	$434K	Buy	6,091 +1,282	+27%	+$94.4K	﹤0.01%	1258
2019 Q1	$377K	Buy	+4,809	New	+$364K	﹤0.01%	1363
2018 Q4	–	Sell	-23,404	Closed	-$4.01M	–	2063
2018 Q3	$4.01M	Buy	23,404 +17,954	+329%	+$2.71M	0.02%	853
2018 Q2	$704K	Buy	+5,450	New	+$608K	﹤0.01%	1463
2017 Q1	–	Sell	-4,328	Closed	-$274K	–	1665
2016 Q4	$274K	Buy	+4,328	New	+$273K	﹤0.01%	1464

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Capital Fund Management (CFM)'s LGND Position: Q3 2019 in Review

Capital Fund Management (CFM) sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 3,334 shares — an estimated $209K sold.

Capital Fund Management (CFM) first reported a position in LGND in Q3 2014 and held it in 9 quarters. The position peaked at $1.66M in Q3 2016. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Capital Fund Management (CFM) reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Capital Fund Management (CFM) sold 3,334 Ligand Pharmaceuticals shares in Q3 2019, an estimated $209K.
Capital Fund Management (CFM) first reported a position in Ligand Pharmaceuticals in Q3 2014 and held it in 9 quarters.
Capital Fund Management (CFM)'s Ligand Pharmaceuticals position peaked at $1.66M in Q3 2016.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2019, filed 13 Nov 2019.